The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Shaker A. Mousa

DuPont Pharmaceuticals Company

141 & Henry Clay Road

Exp. Station




Name/email consistency: high



  • DuPont Pharmaceuticals Company, 141 & Henry Clay Road, Exp. Station, E400/3470, USA. 2002
  • DuPont Pharmaceuticals Company, Wilmington, Delaware 19880-0400, USA. 1998 - 2001


  1. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis. Mousa, S.A., Abulencia, J.P., McCarty, O.J., Turner, N.A., Konstantopoulos, K. J. Cardiovasc. Pharmacol. (2002) [Pubmed]
  2. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Mousa, S.A., Bozarth, J.M., Naik, U.P., Slee, A. Br. J. Pharmacol. (2001) [Pubmed]
  3. Overview: from heparin to low molecular weight heparin: beyond anticoagulation. Mousa, S.A., Fareed, J. Curr. Opin. Investig. Drugs (2001) [Pubmed]
  4. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists. Mousa, S.A., Khurana, S., Forsythe, M.S. Arterioscler. Thromb. Vasc. Biol. (2000) [Pubmed]
  5. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels. Mousa, S.A., Bozarth, J.M., Forsythe, M.S., Slee, A. Cardiovasc. Res. (2000) [Pubmed]
  6. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders. Mousa, S.A. Semin. Thromb. Hemost. (2000) [Pubmed]
  7. Human platelet alphaIIbeta3 integrin binding affinity and specificity of SJ874: antiplatelet efficacy versus aspirin. Mousa, S.A., Forsythe, M., Bozarth, J., Jin, F., Confalone, P.N. Coron. Artery Dis. (2000) [Pubmed]
  8. Role of antiplatelet agents in stroke. Mousa, S.A. Curr. Opin. Investig. Drugs (2000) [Pubmed]
  9. Role of hypoxia and extracellular matrix-integrin binding in the modulation of angiogenic growth factors secretion by retinal pigmented epithelial cells. Mousa, S.A., Lorelli, W., Campochiaro, P.A. J. Cell. Biochem. (1999) [Pubmed]
  10. Intravenous and oral antithrombotic efficacy of the novel platelet GPIIb/IIIa antagonist roxifiban (DMP754) and its free acid form, XV459. Mousa, S.A., Kapil, R., Mu, D.X. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  11. Intranasal antiplatelet/antithrombotic efficacy of a novel platelet GPIIB/IIIA receptor antagonist DMP755. Mousa, S.A., Mu, D.X., Hussain, M.A. Thromb. Res. (1998) [Pubmed]
WikiGenes - Universities